Octreotide acetate injections voluntarily recalled due to glass particles
Click Here to Manage Email Alerts
Octreotide acetate injection 500 µg/mL has been voluntarily recalled due to the presence of glass particles in a syringe, according to a press release.
Mylan Institutional, a Viatris company, has voluntarily recalled lot AJ21002 with an expiration date of March 2024 of octreotide acetate injection 500 µg/mL packaged in a carton of 10 1 mL syringes. This lot was distributed in the U.S. between January and June 2022.
Octreotide acetate injection has been shown to reduce blood levels of growth hormone and insulin-like growth factor I for patients with acromegaly with inadequate responses to surgical resection, pituitary irradiation and bromocriptine mesylate. In addition, octreotide has also been used by patients with metastatic carcinoid tumors to suppress or inhibit severe diarrhea and flushing episodes associated with this disease and to treat profuse water diarrhea linked to vasoactive intestinal peptide-secreting tumors.
This recall is being conducted with the FDA, and Mylan Institutional has notified octreotide acetate injection distributors to arrange for the return or disposal of all recalled products.
Read more about
Click Here to Manage Email Alerts